Cargando…
Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma
Background: Glioma is the primary malignant tumor of the central nervous system and presents high mortality and disability rates under existing treatment measures. Thioredoxin domain-containing 12 (TXNDC12) has been shown to play an important role in various malignant tumors. Therefore, we explored...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493877/ https://www.ncbi.nlm.nih.gov/pubmed/34629960 http://dx.doi.org/10.3389/pore.2021.1609825 |
_version_ | 1784579205667749888 |
---|---|
author | Wang, Xinzhuang Yang, Quan Liu, Nan Bian, Qilong Gao, Ming Hou, Xu |
author_facet | Wang, Xinzhuang Yang, Quan Liu, Nan Bian, Qilong Gao, Ming Hou, Xu |
author_sort | Wang, Xinzhuang |
collection | PubMed |
description | Background: Glioma is the primary malignant tumor of the central nervous system and presents high mortality and disability rates under existing treatment measures. Thioredoxin domain-containing 12 (TXNDC12) has been shown to play an important role in various malignant tumors. Therefore, we explored the clinicopathological characteristics of TXNDC12 in glioma to bring to light new ideas in its treatment. Methods: We obtained data packages related to TXNDC12 expression status in gliomas from public databases. We analyzed glioma TXNDC12 expression and patient survival status and validated the above results using glioma specimens from our institution. Next, we analyzed the value of TXNDC12 in combination with 1p19q and isocitrate dehydrogenase (IDH) on the prognosis of glioma by regression model and receiver operating characteristic curve (ROC). Finally, we explored the function of related genes by GO analysis and KEGG analysis. Results: Compared with normal brain tissue, the expression of TXNDC12 in glioma cells, regarding both mRNA and protein levels, was significantly upregulated. The survival time of patients with high-expression of TXNDC12 in glioma cells was shortened. In the World Health Organization pathological classification, IDH status, 1p19q status, and IDH combined with 1p19q subgroups, the expression of TXNDC12 increased with the deterioration of the above indicators. Tumor local immune analysis showed that the immune cell infiltration in TXNDC12 high-expressing glioma tissue increased, the tumor purity was reduced. GO and KEGG analyses indicated that TXNDC12 may be involved in the malignant prognosis of glioma through glycosylation and antigen processing and presentation. Conclusion: We showed that TXNDC12 is significantly highly expressed in gliomas. This high expression predicts the poor prognosis of glioma patients and is related to the gliomas’ local immune microenvironment. As a tumor-related gene, TXNDC12 may be used as a new prognostic judgment molecule. |
format | Online Article Text |
id | pubmed-8493877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84938772021-10-07 Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma Wang, Xinzhuang Yang, Quan Liu, Nan Bian, Qilong Gao, Ming Hou, Xu Pathol Oncol Res Pathology and Oncology Archive Background: Glioma is the primary malignant tumor of the central nervous system and presents high mortality and disability rates under existing treatment measures. Thioredoxin domain-containing 12 (TXNDC12) has been shown to play an important role in various malignant tumors. Therefore, we explored the clinicopathological characteristics of TXNDC12 in glioma to bring to light new ideas in its treatment. Methods: We obtained data packages related to TXNDC12 expression status in gliomas from public databases. We analyzed glioma TXNDC12 expression and patient survival status and validated the above results using glioma specimens from our institution. Next, we analyzed the value of TXNDC12 in combination with 1p19q and isocitrate dehydrogenase (IDH) on the prognosis of glioma by regression model and receiver operating characteristic curve (ROC). Finally, we explored the function of related genes by GO analysis and KEGG analysis. Results: Compared with normal brain tissue, the expression of TXNDC12 in glioma cells, regarding both mRNA and protein levels, was significantly upregulated. The survival time of patients with high-expression of TXNDC12 in glioma cells was shortened. In the World Health Organization pathological classification, IDH status, 1p19q status, and IDH combined with 1p19q subgroups, the expression of TXNDC12 increased with the deterioration of the above indicators. Tumor local immune analysis showed that the immune cell infiltration in TXNDC12 high-expressing glioma tissue increased, the tumor purity was reduced. GO and KEGG analyses indicated that TXNDC12 may be involved in the malignant prognosis of glioma through glycosylation and antigen processing and presentation. Conclusion: We showed that TXNDC12 is significantly highly expressed in gliomas. This high expression predicts the poor prognosis of glioma patients and is related to the gliomas’ local immune microenvironment. As a tumor-related gene, TXNDC12 may be used as a new prognostic judgment molecule. Frontiers Media S.A. 2021-09-22 /pmc/articles/PMC8493877/ /pubmed/34629960 http://dx.doi.org/10.3389/pore.2021.1609825 Text en Copyright © 2021 Wang, Yang, Liu, Bian, Gao and Hou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pathology and Oncology Archive Wang, Xinzhuang Yang, Quan Liu, Nan Bian, Qilong Gao, Ming Hou, Xu Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title | Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title_full | Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title_fullStr | Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title_full_unstemmed | Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title_short | Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma |
title_sort | clinical value of txndc12 combined with idh and 1p19q as biomarkers for prognosis of glioma |
topic | Pathology and Oncology Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493877/ https://www.ncbi.nlm.nih.gov/pubmed/34629960 http://dx.doi.org/10.3389/pore.2021.1609825 |
work_keys_str_mv | AT wangxinzhuang clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma AT yangquan clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma AT liunan clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma AT bianqilong clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma AT gaoming clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma AT houxu clinicalvalueoftxndc12combinedwithidhand1p19qasbiomarkersforprognosisofglioma |